ThromboGenics
ThromboGenics/Novartis’ Jetrea gains NICE ‘yes’
August 30, 2013Alcon, Jetrea, NICE, Novartis, ThromboGenics
Novartis signs experimental eye drug deal
March 19, 2012Research and Development, Sales and Marketing Novartis, ThromboGenics, vitreomacular adhesion
Novartis will develop an experimental eye drug with ThromboGenics in a pact worth nearly $500 million. The deal has been …
Eye treatment could be commercial breakthrough for ThromboGenics
September 1, 2010Research and Development ThromboGenics, eye care, microplasmin
Belgian biopharma company ThromboGenics could have a major product on its hands in the shape of new eye treatment. The …
Encouraging data for ThromboGenics and BioInvent product
May 7, 2010BioInvent, Lovenox, ThromboGenics, VTE
An antibody-based drug to prevent blood clots after orthopaedic surgery has shown promising results in phase II. TB-402 is a …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
